Dashboard
1
Poor Management Efficiency with a low ROE of 6.50%
- The company has been able to generate a Return on Equity (avg) of 6.50% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 20.92
3
Poor long term growth as Operating profit has grown by an annual rate 4.56% of over the last 5 years
4
Flat results in Jun 25
5
With ROE of 12.52%, it has a very attractive valuation with a 1.95 Price to Book Value
6
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 560,128 Million (Mid Cap)
16.00
NA
0.03%
-0.18
11.06%
1.99
Revenue and Profits:
Net Sales:
68,737 Million
(Quarterly Results - Jun 2025)
Net Profit:
5,863 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.1%
0%
-4.1%
6 Months
-4.94%
0%
-4.94%
1 Year
-7.55%
0%
-7.55%
2 Years
13.35%
0%
13.35%
3 Years
39.0%
0%
39.0%
4 Years
11.83%
0%
11.83%
5 Years
-7.55%
0%
-7.55%
Santen Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.43%
EBIT Growth (5y)
4.56%
EBIT to Interest (avg)
20.92
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.91
Tax Ratio
24.14%
Dividend Payout Ratio
34.62%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
16.84%
ROE (avg)
6.50%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.95
EV to EBIT
9.29
EV to EBITDA
6.84
EV to Capital Employed
2.41
EV to Sales
1.55
PEG Ratio
0.38
Dividend Yield
0.03%
ROCE (Latest)
25.95%
ROE (Latest)
12.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
68,737.00
74,771.00
-8.07%
Operating Profit (PBDIT) excl Other Income
12,028.00
18,157.00
-33.76%
Interest
749.00
407.00
84.03%
Exceptional Items
0.00
0.00
Consolidate Net Profit
5,863.00
10,607.00
-44.73%
Operating Profit Margin (Excl OI)
109.60%
179.90%
-7.03%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -8.07% vs 3.29% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -44.73% vs 1.91% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
300,004.00
301,965.00
-0.65%
Operating Profit (PBDIT) excl Other Income
74,179.00
70,081.00
5.85%
Interest
1,083.00
831.00
30.32%
Exceptional Items
-10,140.00
-15,718.00
35.49%
Consolidate Net Profit
35,844.00
26,695.00
34.27%
Operating Profit Margin (Excl OI)
187.40%
171.90%
1.55%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -0.65% vs 8.22% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 34.27% vs 278.09% in Mar 2024
About Santen Pharmaceutical Co., Ltd. 
Santen Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






